Back to Browse Journals » Vascular Health and Risk Management » Volume 7

Differential clinical profile of candesartan compared to other angiotensin receptor blockers

Authors Cernes R, Mashavi M, Zimlichman R

Published Date December 2011 Volume 2011:7 Pages 749—759

DOI http://dx.doi.org/10.2147/VHRM.S22591

Published 12 December 2011

Relu Cernes1,2, Margarita Mashavi1,3, Reuven Zimlichman1,3
1The Brunner Institute for Cardiovascular Research, Wolfson Medical Center and Tel Aviv University, Tel Aviv, Israel; 2Department of Nephrology, Wolfson Medical Center, Holon, Israel; 3Department of Medicine, Wolfson Medical Center, Holon, Israel

Abstract: The advantages of blood pressure (BP) control on the risks of heart failure and stroke are well established. The renin-angiotensin system plays an important role in volume homeostasis and BP regulation and is a target for several groups of antihypertensive drugs. Angiotensin II receptor blockers represent a major class of antihypertensive compounds. Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system. Oral candesartan 8–32 mg once daily is recommended for the treatment of adult patients with hypertension. Clinical trials have demonstrated that candesartan cilexetil is an effective agent in reducing the risk of cardiovascular mortality, stroke, heart failure, arterial stiffness, renal failure, retinopathy, and migraine in different populations of adult patients including patients with coexisting type 2 diabetes, metabolic syndrome, or kidney impairment. Clinical evidence confirmed that candesartan cilexetil provides better antihypertensive efficacy than losartan and is at least as effective as telmisartan and valsartan. Candesartan cilexetil, one of the current market leaders in BP treatment, is a highly selective compound with high potency, a long duration of action, and a tolerability profile similar to placebo. The most important and recent data from clinical trials regarding candesartan cilexetil will be reviewed in this article.

Keywords: angiotensin receptor blockers, candesartan, candesartan cilexetil, clinical trials, efficacy studies, safety, blood pressure

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Ag-plasma modification enhances bone apposition around titanium dental implants: an animal study in Labrador dogs

Qiao SC, Cao HL, Zhao X, Lo HW, Zhuang LF, Gu YX, Shi JY, Liu XY, Lai HC

International Journal of Nanomedicine 2015, 10:653-664

Published Date: 14 January 2015

Congenital anomaly of the inferior vena cava and factor V Leiden mutation predisposing to deep vein thrombosis

Lamparello BM, Erickson CR, Kulthia A, Virparia V, Thet Z

Vascular Health and Risk Management 2014, 10:609-613

Published Date: 4 November 2014

Lens dislocation has a possible relationship with laser iridotomy

Mutoh T, Barrette KF, Matsumoto Y, Chikuda M

Clinical Ophthalmology 2012, 6:2019-2022

Published Date: 5 December 2012

Critical evaluation of the efficacy and tolerability of azilsartan

De Caterina AR, Harper AR, Cuculi F

Vascular Health and Risk Management 2012, 8:299-305

Published Date: 14 May 2012

Autism and exergaming: effects on repetitive behaviors and cognition

Anderson-Hanley C, Tureck K, Schneiderman RL

Psychology Research and Behavior Management 2011, 4:129-137

Published Date: 16 September 2011

Endothelial function in a cardiovascular risk population with borderline ankle–brachial index

Kari Syvänen, Päivi Korhonen, Auli Partanen, et al

Vascular Health and Risk Management 2011, 7:97-101

Published Date: 23 February 2011

Inferior displacement of the lower eyelid during intraoperative quantification in blepharoptosis surgery

Hirohiko Kakizaki, Yasuhiro Takahashi, Masahiro Zako, et al

Clinical Ophthalmology 2011, 5:193-195

Published Date: 11 February 2011